Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer.
(2015) In Clinical Epigenetics 7.- Abstract
- To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore offer new approaches for detecting and diagnosing disease. Nucleosomes are the repeating subunits of DNA and histone proteins that constitute human chromatin. Because of their release into the circulation, intact nucleosome levels in serum or plasma can serve as diagnostic disease biomarkers, and elevated levels have been reported in various cancers. However, quantifying nucleosomes in the circulation for cancer detection has been challenging due to nonspecific elevation in sera of patients with benign diseases. Here, we report... (More)
- To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore offer new approaches for detecting and diagnosing disease. Nucleosomes are the repeating subunits of DNA and histone proteins that constitute human chromatin. Because of their release into the circulation, intact nucleosome levels in serum or plasma can serve as diagnostic disease biomarkers, and elevated levels have been reported in various cancers. However, quantifying nucleosomes in the circulation for cancer detection has been challenging due to nonspecific elevation in sera of patients with benign diseases. Here, we report for the first time differential, disease-associated epigenetic profiles of intact cell-free nucleosomes (cfnucleosomes) containing specific DNA and histone modifications as well as histone variants circulating in the blood. The study comprised serum samples from 59 individuals, including 25 patients with resectable pancreatic cancer, 10 patients with benign pancreatic disease, and 24 healthy individuals using Nucleosomics(®), a novel ELISA method. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8158479
- author
- Bauden, Monika LU ; Pamart, Dorian ; Ansari, Daniel LU ; Herzog, Marielle ; Eccleston, Mark ; Micallef, Jake ; Andersson, Bodil LU and Andersson, Roland LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Epigenetics
- volume
- 7
- article number
- 106
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:26451166
- wos:000362406200001
- scopus:84943147333
- pmid:26451166
- ISSN
- 1868-7075
- DOI
- 10.1186/s13148-015-0139-4
- project
- Pancreatic cancer
- language
- English
- LU publication?
- yes
- id
- 105aa9fc-0ead-4f51-b5b3-03fea0bcb879 (old id 8158479)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26451166?dopt=Abstract
- date added to LUP
- 2016-04-01 10:47:57
- date last changed
- 2022-04-28 01:28:54
@article{105aa9fc-0ead-4f51-b5b3-03fea0bcb879, abstract = {{To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore offer new approaches for detecting and diagnosing disease. Nucleosomes are the repeating subunits of DNA and histone proteins that constitute human chromatin. Because of their release into the circulation, intact nucleosome levels in serum or plasma can serve as diagnostic disease biomarkers, and elevated levels have been reported in various cancers. However, quantifying nucleosomes in the circulation for cancer detection has been challenging due to nonspecific elevation in sera of patients with benign diseases. Here, we report for the first time differential, disease-associated epigenetic profiles of intact cell-free nucleosomes (cfnucleosomes) containing specific DNA and histone modifications as well as histone variants circulating in the blood. The study comprised serum samples from 59 individuals, including 25 patients with resectable pancreatic cancer, 10 patients with benign pancreatic disease, and 24 healthy individuals using Nucleosomics(®), a novel ELISA method.}}, author = {{Bauden, Monika and Pamart, Dorian and Ansari, Daniel and Herzog, Marielle and Eccleston, Mark and Micallef, Jake and Andersson, Bodil and Andersson, Roland}}, issn = {{1868-7075}}, language = {{eng}}, publisher = {{BioMed Central (BMC)}}, series = {{Clinical Epigenetics}}, title = {{Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer.}}, url = {{https://lup.lub.lu.se/search/files/2143663/8840926}}, doi = {{10.1186/s13148-015-0139-4}}, volume = {{7}}, year = {{2015}}, }